Index of reports
> Cases with Acute Myeloid Leukaemia (26)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Mercaptopurine where reactions include acute myeloid leukaemia. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Mercaptopurine side effects in 49 year old male
Reported by a physician from United States on 2012-07-23
Patient: 49 year old male
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Fludarabine Phosphate
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in 52 year old female
Reported by a physician from United States on 2012-07-23
Patient: 52 year old female
Reactions: Oesophageal Mass, Multi-Organ Failure, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of 3 + 7 regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: part of 3 + 7 regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Possible Mercaptopurine side effects in 25 year old male
Reported by a physician from United States on 2012-07-23
Patient: 25 year old male
Reactions: Acute Myeloid Leukaemia, Petechiae
Drug(s) suspected as cause:
Advil
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Possible Mercaptopurine side effects in male
Reported by a physician from United States on 2012-07-18
Patient: male
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Fludarabine Phosphate
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: part of flag-ida regimen
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)
Idarubicin HCL
Dosage: part of flag-ida regimen
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Possible Mercaptopurine side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18
Patient: male
Reactions: Acute Myeloid Leukaemia
Drug(s) suspected as cause:
Idarubicin HCL
Dosage: 12 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Dosage: 50 mg, unk
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2, unk
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Other drugs received by patient: Advil
Possible Mercaptopurine side effects in male
Reported by a physician from United States on 2012-07-18
Patient: male
Reactions: Acute Myeloid Leukaemia
Drug(s) suspected as cause:
Advil
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Possible Mercaptopurine side effects in female
Reported by a physician from United States on 2012-07-18
Patient: female
Reactions: Multi-Organ Failure, Oesophageal Mass, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of 3 + 7 regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: part of 3 + 7 regimen
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: part of 3 + 7 regimen
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Possible Mercaptopurine side effects in male
Reported by a physician from United States on 2012-07-18
Patient: male
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Fludarabine Phosphate
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: part of flag-ida regimen
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)
Idarubicin HCL
Dosage: part of flag-ida regimen
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Possible Mercaptopurine side effects in female
Reported by a physician from United States on 2012-07-18
Patient: female
Reactions: Multi-Organ Failure, Oesophageal Mass, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of 3 + 7 regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Idarubicin HCL
Dosage: part of 3 + 7 regimen
Idarubicin HCL
Dosage: part of 3 + 7 regimen
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in male
Reported by a physician from United States on 2012-07-18
Patient: male
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Fludarabine Phosphate
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: part of flag-ida regimen
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)
Idarubicin HCL
Dosage: part of flag-ida regimen
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in male
Reported by a physician from United States on 2012-07-18
Patient: male
Reactions: Acute Myeloid Leukaemia
Drug(s) suspected as cause:
Advil
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Possible Mercaptopurine side effects in female
Reported by a physician from United States on 2012-07-18
Patient: female
Reactions: Oesophageal Mass, Multi-Organ Failure, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of 3 + 7 regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: part of 3 + 7 regimen
Idarubicin HCL
Dosage: part of 3 + 7 regimen
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in male
Reported by a physician from United States on 2012-07-18
Patient: male
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Fludarabine Phosphate
Dosage: part of flag-ida regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: part of flag-ida regimen
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)
Idarubicin HCL
Dosage: part of flag-ida regimen
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in male
Reported by a physician from United States on 2012-07-18
Patient: male
Reactions: Acute Myeloid Leukaemia
Drug(s) suspected as cause:
Advil
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Possible Mercaptopurine side effects in female
Reported by a physician from United States on 2012-07-18
Patient: female
Reactions: Oesophageal Mass, Multi-Organ Failure, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: part of 3 + 7 regimen
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Myelodysplastic Syndrome
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Idarubicin HCL
Dosage: part of 3 + 7 regimen
Idarubicin HCL
Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)
Idarubicin HCL
Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)
Idarubicin HCL
Dosage: part of 3 + 7 regimen
Mercaptopurine
Dosage: 50 mg/m2/d (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2/w (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)
Tretinoin
Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-17
Patient: male
Reactions: Anaemia, Acute Myeloid Leukaemia
Adverse event resulted in: death
Drug(s) suspected as cause:
Idarubicin HCL
Dosage: 12 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Dosage: 50 mg, unk
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in 52 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-17
Patient: 52 year old female
Reactions: Multi-Organ Failure, Oesophageal Mass, Acute Myeloid Leukaemia, Pancytopenia, Chloroma
Adverse event resulted in: death
Drug(s) suspected as cause:
Idarubicin HCL
Dosage: 12 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Dosage: 50 mg, unk
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Dosage: 10 mg/m2, unk
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m2, unk
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Other drugs received by patient: Cytarabine
Possible Mercaptopurine side effects in 55 year old female
Reported by a physician from United Kingdom on 2012-06-15
Patient: 55 year old female
Reactions: Acute Myeloid Leukaemia, Pancytopenia, Myelodysplastic Syndrome
Drug(s) suspected as cause:
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Daunorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Etoposide
Indication: Acute Lymphocytic Leukaemia
Mercaptopurine
Dosage: 50 mg
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Vincristine Sulfate
Indication: Acute Lymphocytic Leukaemia
Possible Mercaptopurine side effects in 52 year old female
Reported by a physician from United States on 2012-06-14
Patient: 52 year old female
Reactions: Multi-Organ Failure, Acute Myeloid Leukaemia, Chloroma
Adverse event resulted in: death
Drug(s) suspected as cause:
Idarubicin HCL
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Mercaptopurine
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in 25 year old male
Reported by a physician from United States on 2012-06-14
Patient: 25 year old male
Reactions: Acute Myeloid Leukaemia
Drug(s) suspected as cause:
ALL-Trans Retinoic Acid (Atra)
Administration route: Oral
ALL-Trans Retinoic Acid (Atra)
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Idarubicin HCL
Mercaptopurine
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in 25 year old male
Reported by a physician from United States on 2012-05-29
Patient: 25 year old male
Reactions: Stem Cell Transplant, K-RAS Gene Mutation, Acute Myeloid Leukaemia
Drug(s) suspected as cause:
Idarubicin HCL
Dosage: 12 mg/m 2 milligram(s)/sq. meter
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Dosage: 50 mg/m 2 milligram(s)/sq. meter
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m^2 per week
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone Hydrochloride
Dosage: 10 mg/m 2 milligram(s)/sq. meter
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m 2 milligram(s)/sq. meter
Indication: Acute Myeloid Leukaemia
Possible Mercaptopurine side effects in 49 year old male
Reported by a physician from United States on 2012-05-29
Patient: 49 year old male
Reactions: Stem Cell Transplant, Refractory Anaemia With AN Excess of Blasts, Chromosome Analysis Abnormal, Acute Myeloid Leukaemia, Post Procedural Complication
Adverse event resulted in: death
Drug(s) suspected as cause:
(Granulocyte Colony Stimulating Factor)
Indication: Refractory Anaemia
Cytarabine
Indication: Refractory Anaemia
Fludarabine Phosphate
Indication: Refractory Anaemia
Idarubicin HCL
Dosage: 12 mg/m 2 milligram(s)/sq. meter
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Dosage: 50 mg/m 2 milligram(s)/sq. meter
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m^2 per week
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone Hydrochloride
Dosage: 10 mg/m 2 milligram(s)/sq. meter
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m 2 milligram(s)/sq. meter
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in 52 year old female
Reported by a physician from United States on 2012-05-29
Patient: 52 year old female
Reactions: Oesophageal Mass, Multi-Organ Failure, Gene Mutation, Acute Myeloid Leukaemia, Refractory Cytopenia With Multilineage Dysplasia, Chloroma
Drug(s) suspected as cause:
Cytarabine
Indication: Refractory Cytopenia With Multilineage Dysplasia
Idarubicin HCL
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Dosage: 50 mg/m 2 milligram(s)/sq. meter
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Dosage: 15 mg/m^2 per week
Indication: Acute Promyelocytic Leukaemia
Novantrone
Dosage: 10 mg/m 2 milligram(s)/sq. metere
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Dosage: 45 mg/m 2 milligram(s)/sq. meter
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in 49 year old male
Reported by a individual with unspecified qualification from United States on 2012-05-22
Patient: 49 year old male
Reactions: Acute Myeloid Leukaemia
Adverse event resulted in: death
Drug(s) suspected as cause:
Idarubicin HCL
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Administration route: Oral
Tretinoin
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Possible Mercaptopurine side effects in 25 year old male
Reported by a individual with unspecified qualification from United States on 2012-05-22
Patient: 25 year old male
Reactions: Acute Myeloid Leukaemia
Drug(s) suspected as cause:
Idarubicin HCL
Indication: Acute Promyelocytic Leukaemia
Mercaptopurine
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Administration route: Oral
Other drugs received by patient: Ibuprofen (Advil)
Possible Mercaptopurine side effects in 52 year old female
Reported by a individual with unspecified qualification from United States on 2012-05-22
Patient: 52 year old female
Reactions: Acute Myeloid Leukaemia
Drug(s) suspected as cause:
Cytarabine
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Mercaptopurine
Indication: Acute Promyelocytic Leukaemia
Methotrexate
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Tretinoin
Administration route: Oral
|